REMI

Remedent, Inc. [REMI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

REMI Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

REMI has more than 2 years of cash runway (25 months)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Does not have any significance market cap ($1.1M)

In the News

REMI Financial details

Company Rating

Buy

Market Cap

1.1M

Income

-553.6K

Revenue

940.41K

Book val./share

0.13

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

29 May 2024

P/E

-2.27

Forward P/E

PEG

-0.2

P/S

2.07

P/B

0.43

P/C

P/FCF

21.65

Quick Ratio

0.15

Current Ratio

0.24

Debt / Equity

0.01

LT Debt / Equity

EPS (TTM)

-0.03

EPS next Y

EPS next Q

EPS this Y

479.84%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

-11.64%

Revenue Q/Q

78.05%

EPS Q/Q

-220%

SMA20

-16.67%

SMA50

-54.55%

SMA100

Inst Own

19.76%

Inst Trans

ROA

-11%

ROE

-17%

ROC

-0.1%

Gross Margin

70%

Oper. Margin

-45%

Profit Margin

-80%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.02-0.17

52W High

52W Low

RSI

48.49

Rel Volume

0.16

Avg Volume

6.45K

Volume

1000

Perf Week

37.5%

Perf Month

-31.25%

Perf Quarter

Perf Half Y

-63.33%

Beta

-0.186

Volatility

0.01%, 0.02%

Prev Close

-15.84%

Price

0.055

Change

-15.84%

REMI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.08	0.05	0.05	0.07	0.04
Net income per share	0.11	-0.04	-0.01	-0.01	-0.07
Operating cash flow per share	0.03	0.01	0	-0.01	0
Free cash flow per share	0.03	0.01	0	-0.01	0
Cash per share	0	0.01	0	0.01	0.01
Book value per share	0.28	0.23	0.22	0.21	0.13
Tangible book value per share	0.28	0.23	0.22	0.21	0.14
Share holders equity per share	0.28	0.23	0.22	0.21	0.13
Interest debt per share	0	0.01	0	0	0
Market cap	3.85M	3.6M	3.8M	3.4M	3.4M
Enterprise value	3.84M	3.49M	3.73M	3.23M	3.29M
P/E ratio	1.81	-4.21	-23.29	-13.22	-2.27
Price to sales ratio	2.4	3.38	3.69	2.41	3.94
POCF ratio	6.79	35.44	2.21K	-20.12	-64.05
PFCF ratio	6.79	35.44	2.21K	-20.12	-64.05
P/B Ratio	0.71	0.79	0.88	0.83	1.31
PTB ratio	0.71	0.79	0.88	0.83	1.31
EV to sales	2.39	3.28	3.62	2.29	3.81
Enterprise value over EBITDA	-6.2	-4.55	991.19	9.32	-12.78
EV to operating cash flow	6.76	34.37	2.17K	-19.09	-62.07
EV to free cash flow	6.76	34.37	2.17K	-19.09	-62.07
Earnings yield	0.55	-0.24	-0.04	-0.08	-0.44
Free cash flow yield	0.15	0.03	0	-0.05	-0.02
Debt to equity	0.01	0.03	0	0.01	0.02
Debt to assets	0.01	0.02	0	0	0.01
Net debt to EBITDA	0.02	0.14	-19.25	-0.5	0.41
Current ratio	0.27	0.24	0.21	0.38	0.32
Interest coverage	-67.4	-34.05	-8.58	42.87	-68.5
Income quality	0.27	-0.12	-0.01	0.66	0.04
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.63	0.7	0	0	0
Research and developement to revenue	0	0	0	0.01	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.83	0.47	0.2	0.24	0.47
ROIC	-0.13	-0.1	-0.01	0.09	-0.11
Return on tangible assets	0.27	-0.11	-0.02	-0.04	-0.27
Graham Net	-0.11	-0.12	-0.12	-0.1	-0.11
Working capital	-1.78M	-2.2M	-2.18M	-1.68M	-1.93M
Tangible asset value	5.46M	4.62M	4.43M	4.25M	2.73M
Net current asset value	-1.78M	-2.21M	-2.18M	-1.68M	-1.93M
Invested capital	0.01	0.03	0	0.01	0.02
Average receivables	696.53K	281.62K	357.74K	565.83K	733.85K
Average payables	1.74M	2.11M	2.27M	2.19M	2.16M
Average inventory	117.04K	100.9K	96.59K	98.42K	93.65K
Days sales outstanding	53.24	112.93	136.85	193.31	305.15
Days payables outstanding	1.2K	2.6K	1.81K	2.16K	2.22K
Days of inventory on hand	69.32	102.89	82.77	95.63	94.54
Receivables turnover	6.86	3.23	2.67	1.89	1.2
Payables turnover	0.3	0.14	0.2	0.17	0.16
Inventory turnover	5.27	3.55	4.41	3.82	3.86
ROE	0.39	-0.19	-0.04	-0.06	-0.58
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0.01	0.01	0.01	0.02
Net income per share	-0.01	-0.02	0	0	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0.01	0.01	0	0	0
Book value per share	0.16	0.13	0.13	0.13	0.13
Tangible book value per share	0.16	0.14	0.13	0.13	0.13
Share holders equity per share	0.16	0.13	0.13	0.13	0.13
Interest debt per share	0	0	0	0	0
Market cap	3.4M	3.4M	3.4M	3M	2M
Enterprise value	3.3M	3.29M	3.33M	2.96M	1.93M
P/E ratio	-3.18	-1.7	-13.79	-25.41	13.87
Price to sales ratio	14.41	16.33	15.65	16.19	6.06
POCF ratio	66.89	51.7	-64.08	-38.58	21.55
PFCF ratio	66.89	51.7	-64.08	-38.58	21.55
P/B Ratio	1.09	1.31	1.34	1.19	0.79
PTB ratio	1.09	1.31	1.34	1.19	0.79
EV to sales	13.99	15.83	15.32	15.99	5.86
Enterprise value over EBITDA	-56.19	-43.66	-177.07	-1.1K	50.22
EV to operating cash flow	64.91	50.09	-62.72	-38.11	20.82
EV to free cash flow	64.91	50.09	-62.72	-38.11	20.82
Earnings yield	-0.08	-0.15	-0.02	-0.01	0.02
Free cash flow yield	0.01	0.02	-0.02	-0.03	0.05
Debt to equity	0.01	0.02	0.01	0.01	0.01
Debt to assets	0.01	0.01	0	0	0.01
Net debt to EBITDA	1.72	1.4	3.84	13.65	-1.77
Current ratio	0.3	0.32	0.3	0.3	0.36
Interest coverage	-79.66	-59.77	-29.7	-12.51	38.31
Income quality	-0.19	-0.13	0.86	2.63	2.57
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.22	0.27	0.09	0.06	0.07
ROIC	-0.02	-0.03	-0.01	0	0.01
Return on tangible assets	-0.05	-0.09	-0.01	-0.01	0.01
Graham Net	-0.1	-0.11	-0.11	-0.11	-0.11
Working capital	-1.87M	-1.93M	-1.95M	-1.92M	-1.94M
Tangible asset value	3.27M	2.73M	2.7M	2.68M	2.69M
Net current asset value	-1.87M	-1.93M	-1.95M	-1.92M	-1.94M
Invested capital	0.01	0.02	0.01	0.01	0.01
Average receivables	574.61K	663.27K	701.12K	682.22K	796.78K
Average payables	2.08M	2.16M	2.23M	2.22M	2.3M
Average inventory	86.72K	90.61K	92.21K	90.3K	90.22K
Days sales outstanding	230.63	312.3	281.78	332.5	248.08
Days payables outstanding	2.25K	2.06K	2.05K	2.51K	1.94K
Days of inventory on hand	92.53	87.73	82.53	103.31	72.7
Receivables turnover	0.39	0.29	0.32	0.27	0.36
Payables turnover	0.04	0.04	0.04	0.04	0.05
Inventory turnover	0.97	1.03	1.09	0.87	1.24
ROE	-0.09	-0.19	-0.02	-0.01	0.01
Capex per share	0	0	0	0	0

REMI Frequently Asked Questions

What is Remedent, Inc. stock symbol ?

Remedent, Inc. is a BE stock and trading under the symbol REMI

What is Remedent, Inc. stock quote today ?

Remedent, Inc. stock price is $0.055 today.

Is Remedent, Inc. stock public?

Yes, Remedent, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 6.45K
Market Capitalization 1.1M
Employee 3
CEO Mr. Guy De Vreese
Headquarters Gent,BE
IPO Date 2006-03-01
Website https://www.remedent.com

Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth. In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. Further, it provides dental implant solutions and treatment concepts. The company sells its products to dental professionals in approximately 30 countries, including Asia, Europe, the Middle East, Canada, and the United States through its internal sales force and third party distributors. The company was founded in 1986 and is headquartered in Ghent, Belgium.